Availability and buying

retatrutide where to get

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

For now, the official route is clinical-trial participation, not public purchasing.

Direct answer

Retatrutide is not yet available for public use. Lilly says it is legally available only to participants in Lilly clinical trials.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quotequality of the prescription drugs sold online

Lim et al., 2022 systematic review of online pharmacies selling prescription drugs

This systematic review supports online-source caution for prescription-drug searches and marketplace claims.

Short source quoteselling counterfeit, adulterated or unapproved drugs

Limbu and Huhmann, 2023 scoping review of illicit online pharmacies

This scoping review supports warnings about illicit online pharmacies and unapproved prescription-drug access.

Short source quotepreparation errors

McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study

This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.

What to know before acting on this search

Clinical trial availability depends on eligibility, location, study status, and investigator screening.
Online seller pages can exist even when the underlying drug is not approved.
A licensed clinician can help compare approved treatment options while retatrutide remains investigational.

Safety and compliance notes

Retatrutide is investigational and is not FDA approved for public sale or prescription.
Lilly says retatrutide is legally available only to participants in Lilly clinical trials while safety and efficacy are evaluated.
FDA warns that some products sold as research-use or not-for-human-consumption GLP-1 drugs may be unapproved, unknown-quality, and harmful.

Safer next step

Check the clinical-trials page first, then the approved-alternatives page for clinician-supervised options.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.